|
|
楼主 |
发表于 2025-2-21 00:22:58
|
显示全部楼层
马骏院士团队被接收一篇JAMA、一篇Cancer Cell，另有8项临床试验在进行中4 U/ A# Q, p" b# K
Whole-course Concurrent and Adjuvant Nivolumab Combined with Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03984357, Cancer Cell, 2025,已接收)
9 |) p" J0 y3 E8 u
* {; o, R, f& H8 PAdjuvant PD-1 Antibody in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (NCT03427827, JAMA, 2025,已接收)
$ Z" U: n J# e( \
) A; X5 m: ]. e$ v! JGP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (NCT06455410, 进行中)
$ L! T# y+ x6 \Individualized Elective Neck Irradiation in NPC Patients (NCT06241612, 进行中)( Y* ^2 d: J- w1 d$ p3 j
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (NCT06239727, 进行中)
- L7 C8 S3 ^/ HCadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05587374, 进行中): x* o5 Q9 k7 L' j$ H2 q7 y
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480, completed)7 O! \8 v$ |" f1 |
Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NPC-LN) (NCT05389306, 进行中). o( T, ~0 X# T( W& H
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792, 进行中)" l7 b% s/ k. N! J
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117, 进行中) |
|
发表于 2025-2-20 23:39:43
